Hoppa till innehållet
Radio Logo
PoddsändningarLife ScienceDNA Today: A Genetics Podcast

DNA Today: A Genetics Podcast

Kira Dineen, Gene Pool Media
Senaste avsnittet

421 avsnitt

  • DNA Today: A Genetics Podcast

    #420 NSGC 2026: Ambry's Whole Genome Sequencing and BillionToOne's Unity Confirm

    2026-11-14 | 31 min.
    In this episode, we're coming to you from Baltimore for the National Society of Genetic Counselors (NSGC) 2026 Annual Conference! From new approaches to whole genome sequencing to the ability to analyze intact fetal cells through a pregnant person’s blood sample, we're exploring two exciting advances in genetic testing that could change how patients receive answers.

    Host Kira Dineen sits down with experts from Ambry Genetics and BillionToOne to discuss new technologies unveiled at the conference, their clinical applications, and how they could improve diagnostic accuracy and accessibility.

    We also celebrate Genetic Counselor Appreciation Day, highlight memorable moments from NSGC 2026, and share a special thank-you following Kira's recognition with the NSGC Leader in Community Engagement Award!

    Featured Guests
    Thomas "TJ" Slavin Jr., MD, is the Chief Medical Officer of Ambry Genetics and a medical geneticist. He joins us to discuss Ambry Genetics' newly launched whole genome sequencing offerings, GenomeNext and GenomeReveal, and how integrating RNA analysis, pangenome references, and proactive reanalysis could help end the diagnostic odyssey for more families.

    Jennifer "Jen" Hoskovec, MS, CGC, is Vice President of Medical Affairs at BillionToOne and a past president of NSGC (2014). She returns to DNA Today to introduce Unity Confirm, a new prenatal testing option that isolates and sequences intact circulating placental cells from a pregnant person’s blood to provide additional information following high-risk NIPT results.

    In This Episode We Discuss
    Ambry Genetics: Whole Genome Sequencing, RNA Analysis, and the Pangenome

    How Tempus' acquisition of Ambry Genetics brings together tumor sequencing and germline testing capabilities.

    Why Ambry chose 2026 to launch GenomeNext and GenomeReveal and how whole genome sequencing is changing rare disease diagnostics.

    How RNA analysis can help clarify variants of uncertain significance (VUS), particularly variants that may affect RNA splicing.

    Why incorporating a human pangenome reference can improve variant detection across diverse ancestral populations and help address disparities in genetic testing.

    How Ambry's Patient for Life program proactively reanalyzes genetic data and contacts providers when new evidence leads to clinically meaningful changes.

    Why identifying dual genetic diagnoses is increasingly important and how ongoing reanalysis can reveal additional explanations for a patient's symptoms.

    BillionToOne: Unity Confirm and Cell-Based Prenatal Testing

    How Unity Confirm differs from traditional cell-free DNA screening by isolating intact circulating extravillous trophoblasts from a pregnant person’s blood.

    How sequencing individual placental cells can provide additional information following a high-risk NIPT result.

    Why Unity Confirm is positioned as an additional testing option rather than a replacement for diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis.

    How this technology could help patients who decline invasive testing or face geographic, financial, or gestational-age barriers to accessing diagnostic procedures.

    The limitations of analyzing a small number of cells, particularly when considering placental mosaicism and conditions such as Turner syndrome.

    How staining techniques and genetic comparisons help distinguish placental trophoblasts from maternal white blood cells.

    How genetic counselors can integrate another source of prenatal information into patient-centered conversations about screening, diagnosis, and reproductive decision-making.

     

    Resources & Links
    NSGC Annual Conference
    National Society of Genetic Counselors (NSGC) – Learn more about NSGC, its annual conference, and resources for genetic counseling professionals.

    Ambry Genetics and Whole Genome Sequencing

    Ambry Genetics – Explore Ambry's clinical genetic testing services and resources.

    GenomeNext and GenomeReveal Launch Announcement – Learn how Ambry integrates whole genome sequencing, RNA analysis, pangenome references, and ongoing reanalysis to improve rare disease diagnosis.

    GenomeNext and GenomeReveal – Explore the technologies and clinical capabilities behind Ambry's new whole genome sequencing offerings.

    Patient for Life White Paper – Learn how Ambry's proactive reanalysis program identifies new diagnostic findings as genetic knowledge evolves.

    Tempus AI – Learn about Ambry's parent company and its work in precision medicine.

    Fact Check: Kira misspoke when she said Ambry has been analyzing RNA as part of clinical testing for 15 years, she was thinking of Ambry offering the first clinical exome as that was launched in 2011. 

    BillionToOne and Prenatal Testing

    BillionToOne – Explore the company's prenatal genetic testing technologies.

    Unity Confirm White Paper: Initial Clinical Outcomes of a Circulating Fetal Cell Assay – Review the initial clinical findings and learn how circulating placental cells are isolated, identified, and sequenced. Includes details on distinguishing maternal cells from placental trophoblasts. This is the white paper Jen referenced in the episode. 

    Unity Confirm Launch Announcement – Learn how this new blood test provides additional information following high-risk prenatal screening results.

    Unity Genetic Counselor Resources – Access clinical information, educational materials, and prenatal testing resources for genetic counselors.

    BillionToOne Clinical Publications – Explore the research supporting Unity Confirm and other BillionToOne prenatal testing technologies.

    Relevant DNA Today Episodes
    We've been recapping the NSGC Annual Conference every year since 2019! Catch up on our previous conference coverage to see how the field of genetic counseling has evolved over the years: #111 NSGC 2019 Recap, #135 NSGC 2020 Recap, #157 NSGC 2021 Recap, #212 NSGC 2022 Recap, #259 NSGC 2023 Recap, #307 NSGC 2024 Recap, and #366 NSGC 2025 Recap.

    - #182 Eric Green on the Complete Human Genome Project - Dr. Eric Green discusses the completion of the human genome sequence and the Telomere-to-Telomere Consortium, foundational advances that paved the way for today's whole genome sequencing technologies.

    - #370 Genetics Wrapped: 2025 Top Advances in Genomic Medicine - Dr. Eric Green returns to review major genomic breakthroughs, including the Human Pangenome Project and its importance for improving representation and equity in genetic testing.

    - #303 RNA Analysis with Ambry Genetics - Dr. Rachid Karam explains how Ambry integrates RNA analysis to clarify uncertain variants and improve diagnostic yield, a technology now incorporated into GenomeReveal.

    - #297 Exome Reanalysis with Ambry Genetics - Kelly Hagman and Dr. Elizabeth Chao discuss Ambry's Patient for Life program and how proactive genetic reanalysis can uncover diagnoses as scientific knowledge evolves.

    - #385 Inside ACMG 2026: How AI and New Tools Enhance Genome Sequencing and Equity - Explores how RNA sequencing, long-read sequencing, artificial intelligence, and other emerging tools are improving whole genome interpretation and addressing diagnostic disparities.

    - #224 Single-Gene Noninvasive Prenatal Testing (NIPT) with BillionToOne - Jennifer Hoskovec and Dr. Oguzhan Atay explain BillionToOne's approach to single-gene NIPT, providing background on the company's prenatal testing innovations before the introduction of Unity Confirm.

    - #225 Fetal Antigen Noninvasive Prenatal Testing (NIPT) with BillionToOne - Jennifer Hoskovec returns to discuss noninvasive fetal antigen testing, highlighting another advance in prenatal testing from BillionToOne before its latest cell-based technology.

     

    Connect with DNA Today:
    You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.”

    Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios.

    Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network.

    DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Our associate producer for this episode is Jess Rizzo, CGC. Liv Davidson is our Social Media Lead. 

    Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. 

    Questions, partnership inquiries, and guest pitches can be sent to [email protected].
  • DNA Today: A Genetics Podcast

    #419 Optical Genome Mapping and Long-Read Sequencing: Unlocking Rare Diagnoses

    2026-11-06 | 39 min.
    What happens when traditional genetic testing leaves patients and families without answers? Emerging technologies like optical genome mapping (OGM) and long-read sequencing are expanding what laboratories can detect, from complex structural variants to difficult-to-analyze repetitive regions of the genome. These advances are already changing clinical testing strategies and helping uncover diagnoses that previously remained out of reach.

    In this episode, we welcome back Dr. Nikhil Sahajpal, Assistant Laboratory Director at Greenwood Genetic Center (GGC), who previously joined us in Episode 362 to introduce optical genome mapping. Now, nearly two years after GGC began offering OGM clinically, Dr. Sahajpal shares how the technology is being integrated into rare disease diagnostics, including additional diagnostic findings in at least 5% of previously unsolved cases.

    The conversation takes a closer look at facioscapulohumeral muscular dystrophy (FSHD), a genetically complex condition involving D4Z4 repeat contractions, epigenetic changes, and inappropriate DUX4 expression. Dr. Sahajpal explains how OGM and short-read sequencing can work together to distinguish FSHD1 from FSHD2, and why the laboratory is evaluating long-read sequencing as a potential way to streamline this testing.

    We also explore targeted applications of OGM and long-read sequencing, including clarifying DMD duplications, mapping structural variant breakpoints, and determining whether variants are in cis or trans. Finally, Dr. Sahajpal discusses where long-read genome sequencing fits into the rare disease diagnostic workflow and whether a more comprehensive, unified genetic test could eventually reduce the need for multiple testing platforms.

    Episode Discussion Topics

    How optical genome mapping compares with karyotyping, FISH, and chromosomal microarray

    Greenwood Genetic Center's clinical experience with OGM and its additional diagnostic yield in previously unsolved rare disease cases

    When OGM may serve as a reflex test following negative genome sequencing

    The genetics of FSHD1, including D4Z4 repeat contractions, permissive haplotypes, and DUX4 expression

    Why chromosome 4 and chromosome 10 repeat regions complicate FSHD testing

    How OGM and short-read sequencing contribute to distinguishing FSHD1 and FSHD2

    The potential for long-read sequencing to assess repeat size, sequence variants, and DNA methylation

    When long-read genome sequencing may be appropriate for patients with broad or nonspecific phenotypes

    How targeted OGM can clarify DMD duplications and change carrier screening interpretation

    Using targeted long-read sequencing to phase variants in recessive conditions without parental samples

    The limitations of phenotype-driven variant analysis and the future of comprehensive genomic testing

    Resources & Links

    Greenwood Genetic Center

    OGM Complete

    OGM Targeted 

    Facioscapulohumeral Muscular Dystrophy Type 2 (FSHD2) NGS Panel

    FSHD1

    Long-read Sequencing-Trio Analysis 

    Long-read Sequencing-Targeted Analysis

    Sahajpal Completes Laboratory Fellowship at GGC and Joins Faculty

    Sahajpal NS, Mondal AK, Singh H, Vashisht A, Ananth S, Saul D, Hastie AR, Hilton B, DuPont BR, Savage NM, Kota V, Chaubey A, Cortes JE, Kolhe R. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers. Cancers (Basel). 2023 Jun 16;15(12):3214. doi: 10.3390/cancers15123214. PMID: 37370824; PMCID: PMC10296552.

    Relevant DNA Today Podcast Episode

    #362 Optical Genome Mapping: Detecting Structural Variants Missed by Traditional Tests (with guest Dr. Nikhil Sahajpal)

    #279 Reflecting on 50 Years of Greenwood Genetic Center

    #183 Dr. Miga and Dr. Phillippy on the Telomere to Telomere Consortium

    #182 Eric Green on the Complete Human Genome Project 

    #145 Greenwood Genetic Center on Epigenetics

    Connect with DNA Today:
    You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.”

    Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios.

    Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network.

    DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. 

    Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. 

    Questions, partnership inquiries, and guest pitches can be sent to [email protected].
  • DNA Today: A Genetics Podcast

    #418 Hypophosphatasia Genetics: One Gene, Many Presentations

    2026-10-30 | 34 min.
    How can variants in the same gene cause life-threatening disease in infancy for some individuals, while others experience mild symptoms or remain asymptomatic? Hypophosphatasia (HPP) challenges traditional expectations about genetic inheritance, with both autosomal dominant and autosomal recessive forms and a remarkably broad spectrum of clinical presentations.

    In this episode, recorded in person in Nashville, our guest is Dr. Kathryn Dahir, Professor of Medicine in the Division of Diabetes, Endocrinology, and Metabolism at Vanderbilt University Medical Center and Director of the Program for Metabolic Bone Disorders. Drawing on decades of experience caring for patients with rare skeletal conditions, Dr. Dahir explores the complex genetics of HPP and why understanding a patient's clinical presentation is just as important as interpreting their genetic test results.

    The conversation begins with a patient case that challenged Dr. Dahir's understanding of HPP. Initially treated for osteoporosis, the patient experienced recurrent fractures and worsening symptoms despite treatment. Further investigation revealed impaired bone mineralization, low alkaline phosphatase (ALP), and a single ALPL variant, illustrating how individuals with one affected copy of the gene can experience significant disease. Dr. Dahir explains how the ALPL gene encodes tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme essential for healthy bone mineralization, and how disruption of its activity contributes to the manifestations of HPP.

    We explore the differences between autosomal dominant and autosomal recessive inheritance, the challenges of predicting disease severity from genetic testing alone, and why even relatives carrying the same ALPL variant may have very different symptoms. Dr. Dahir discusses the importance of identifying variants in cis or trans, recognizing deletions and duplications, evaluating variants of uncertain significance, and considering how genetic modifiers, environmental exposures, and coexisting conditions can influence a patient's presentation.

    Finally, we discuss the evolving landscape of HPP genetic testing, including the importance of longitudinal follow-up, resources such as the global ALPL variant database, and ongoing efforts to improve variant classification. As genomic testing becomes increasingly accessible, this conversation highlights both its potential to improve rare disease diagnosis and the limitations of using genetics alone to predict an individual's future health.

    Episode Discussion Topics

    Dr. Dahir's clinical experience treating HPP and other rare metabolic bone disorders at Vanderbilt University Medical Center

    Why genetic testing must be interpreted alongside clinical symptoms, biochemical findings, and patient history

    A patient case illustrating how HPP can be mistaken for osteoporosis and why low alkaline phosphatase is an important diagnostic clue

    How the ALPL gene and tissue-nonspecific alkaline phosphatase (TNSALP) regulate bone mineralization

    The differences between autosomal dominant and autosomal recessive HPP and the challenges of distinguishing affected individuals from asymptomatic carriers

    Why genotype-phenotype correlations in HPP are complex, even among family members with the same genetic variant

    The importance of determining whether variants are in cis or trans and identifying deletions or duplications that some testing platforms may miss

    How modifier genes, epigenetics, medication exposures, and coexisting medical conditions may influence HPP symptoms and severity

    Interpreting variants of uncertain significance and the importance of genetic counseling, variant reclassification, and long-term follow-up

    The role of the global ALPL variant database in improving classification and understanding the clinical significance of genetic variants

    Future opportunities to identify protective genetic factors and improve predictions of disease progression

    About the HPP Series
    This episode is the first in a three-part educational series about hypophosphatasia. Stay tuned for the next installment . Across the series, we explore the clinical spectrum and diagnosis of HPP, its genetic basis and variable expression, and considerations for genetic counseling and management.

     

    This series is sponsored by Alexion. The views expressed by the host and guests are their own.

    Resources & Links

    Vanderbilt University Medical Center

    Alexion, AstraZeneca Rare Disease 

    ALPL Gene Variant Database

    Soft Bones: The U.S. Hypophosphatasia Foundation provides education, support, advocacy, and community resources for individuals and families affected by HPP.

    Explore Soft Bones’ HPP resources, including educational materials for patients, caregivers, and healthcare professionals.

    Publications

    Dahir KM, Below JE, Liu J, Javid A, Wang G, Bastarache L. Hypophosphatasia: low penetrance of pathogenic and likely-pathogenic ALPL variants identified through an unselected biorepository. J Bone Miner Res. 2026 Mar 2;41(3):270-281. doi: 10.1093/jbmr/zjaf176. Erratum in: J Bone Miner Res. 2026 Oct 11:zjag146. doi: 10.1093/jbmr/zjag146. PMID: 41269245; PMCID: PMC13016712. 

    Dahir KM, Nunes ME. Hypophosphatasia. GeneReviews®. Updated March 27, 2025. This comprehensive clinical overview covers the presentation, diagnosis, genetics, management, and genetic counseling considerations for HPP.

    Beck NM, Sagaser KG, Lawson CS, et al. Not just a carrier: Clinical presentation and management of patients with heterozygous disease-causing alkaline phosphatase (ALPL) variants identified through expanded carrier screening. Molecular Genetics & Genomic Medicine. 2023;11(1):e2056.

    Khan AA, Brandi ML, Rush ET, et al. Hypophosphatasia diagnosis: Current state of the art and proposed diagnostic criteria for children and adults. Osteoporosis International. 2024;35(3):431–438.

    Rush E, Brandi ML, Khan A, et al. Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: Results from the HPP International Working Group. Osteoporosis International. 2024;35(1):1–10.

    Brandi ML, Khan AA, Rush ET, et al. The challenge of hypophosphatasia diagnosis in adults: Results from the HPP International Working Group Literature Surveillance. Osteoporosis International. 2024;35(3):439–449.

    Relevant DNA Today Podcast Episode

    #408 Diagnosing Hypophosphatasia: Low ALP, Fractures, and Early Tooth Loss: Genetic counselor Amy Patterson kicks off our three-part hypophosphatasia series, sponsored by Alexion, exploring the clinical spectrum and diagnosis of HPP. 

    #192 Osteogenesis Imperfecta with The Middle’s Atticus Shaffer: Actor Atticus Shaffer discusses living with osteogenesis imperfecta, his diagnostic and treatment experiences, and what he wants healthcare providers to understand about the condition.

    #301 Dwarfism with Colleen Gioffreda: Colleen Gioffreda shares her personal and professional perspectives on achondroplasia, skeletal dysplasias, parenting, adoption, accessibility, and advocacy.

    #348 NIPT Beyond the Basics: Screening for Single-Gene Conditions: Dr. Fred Ushakov explains how single-gene NIPT and prenatal imaging may identify conditions including achondroplasia, osteogenesis imperfecta, and other skeletal dysplasias.

    #359 Breaking Down Achondroplasia: A Pediatrician in Clinical Genetics Explains: In the first episode of our BioMarin-sponsored achondroplasia series, Dr. Janet Legare explores the genetics, clinical presentation, diagnosis, and multidisciplinary care of achondroplasia.

    #386 Achondroplasia Beyond Height: Managing Lifelong Medical Needs: In the second episode of the BioMarin-sponsored series, Dr. Ricki Carroll discusses lifelong monitoring, medical complications, care coordination, and quality of life.

    #401 The First Precision Medicine for Achondroplasia with Dr. Ravi Savarirayan: The final episode of the BioMarin-sponsored series examines vosoritide, international treatment guidelines, and the evolution of precision medicine for achondroplasia.

    #390 Prince, Mayte Garcia, and Their Son Amiir’s Pfeiffer Syndrome Type 2 Story: Mayte Garcia reflects on her and Prince’s experience with their son Amiir’s severe skeletal and craniofacial condition, Pfeiffer syndrome type 2.

    #394 How Newborn Sequencing Could Transform Pediatric Rare Disease Care in Florida: Dr. Pradeep Bhide and Representative Adam Anderson explore how Florida’s Sunshine Genetics Act could reshape newborn sequencing, rare disease diagnosis, and the future of pediatric genomic medicine.

    Connect with DNA Today:
    You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.”

    Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios.

    Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network.

    DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. 

    Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. 

    Questions, partnership inquiries, and guest pitches can be sent to [email protected].
  • DNA Today: A Genetics Podcast

    #417 ASHG 2026: Electronic Genome Mapping, AI in Genetics, & the Future of Research

    2026-10-23 | 41 min.
    For the third year in a row, DNA Today is bringing you inside the American Society of Human Genetics (ASHG) Annual Meeting, and this year, we've taken our genetics coverage international! We're reporting from beautiful Montréal, Canada, where thousands of geneticists, researchers, clinicians, and industry leaders gathered to share the latest breakthroughs shaping the future of genomics. From cutting-edge technologies to big questions about the future of genetic medicine, there's no shortage of exciting science to unpack. And don't worry, we're bringing you all the highlights, no passport required, eh?

    In this episode, host Kira Dineen takes you behind the scenes of ASHG 2026 through two special segments recorded at the conference.

    First, we stop by the Nabsys booth to chat with Founder and CEO Barrett Bready, MD, about how Electronic Genome Mapping (EGM) is advancing our ability to detect structural variants. We explore how the technology compares with traditional approaches, its emerging applications in hematologic malignancies, and the latest research Nabsys is showcasing at ASHG.

    For our second segment, we're live on location! DNA Today teamed up with Wiley's Advanced Portfolio to co-host a special brunch featuring a live podcast recording right from the conference. With breakfast on the table and big questions on the menu, Kira moderated a conversation with leading genetics researchers and publishing experts about the discoveries, challenges, and opportunities shaping the field. From translating genetic findings into new therapies and harnessing AI to accelerate research to fostering interdisciplinary collaboration and rethinking the role of scientific publishing, this discussion goes beyond the conference presentations to explore where genetics is headed next.

    Whether you joined us in Montréal or are experiencing the conference from afar, consider this your front-row seat to some of the conversations shaping the future of genetics. We're serving up fresh science with a side of maple syrup, because when it comes to genetics, there's always more to discover, eh?

    Nabsys Segment Guest 
    Barrett Bready, MD is Founder and CEO of Nabsys. He is passionate about the impact that advanced technology can have on the understanding of disease as well as on its diagnosis and treatment.  He has raised $150 million to realize a new way of analyzing DNA that uses proprietary solid-state electronic nanodetectors to analyze very long molecules, with an initial focus on genomic structural variation. Barrett is an adjunct professor at Brown University where he lectures on the rapidly evolving business of life sciences. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Barrett graduated from the highly competitive Program in Liberal Medical Education (PLME) at Brown University where he received an M.D. and an Sc.B. in Physics and won the undergraduate physics award (the Lindsay Prize) and the Galletti Prize for physics in medicine.

    Nabsys Discussion Topics

    ASHG 2026 conference highlights and a presentation on electronic genome mapping (EGM) in hematologic malignancies

    Why genomic structural variants matter in cancer and rare disease

    How traditional sequencing and cytogenetic approaches may leave gaps in detecting structural variation

    Nabsys’ electronic genome mapping as a high-resolution, top-down approach to studying genome structure

    How EGM uses electrical detection to read sequence-specific tags on long DNA molecules

    Identifying deletions, insertions, inversions, and translocations by comparing tag patterns

    How EGM relates to traditional cytogenetic methods such as FISH and karyotyping

    The nanochannel detection process and how DNA molecules affect ionic current as they pass through

    Nabsys’ relationship with Hitachi and the potential to scale the technology

    Nabsys’ goal of expanding access to structural variant detection and single-molecule insights

    ASHG posters on CRISPR-Cas9-mediated assay specificity and EGM applications for copy number variants in constitutional disorders

    The potential for EGM to combine modalities and increase diagnostic yield over time

    Wiley Advanced Genetics Panelists 
    Yuming Hu, PhD serves as the Editor-In-Chief for Advanced Genetics, which is a peer-reviewed, broad-scope, open-access journal dedicated to advancing gene-related research with a recently expanded scope. It includes not only human, animal, plant, and microbial genetics, genomics, and epigenomics, but also topics that employ genetic, omics technologies, bioinformatics, computational biology, and artificial intelligence as toolboxes for discovery and innovation. Dr. Hu received her B.Sc. and M.Sc. in Biotechnology from Wageningen University and her Ph.D. in Biochemistry and Biotechnology from Ghent University. She worked as a Research Assistant at the University of California, Davis, and completed a postdoctoral fellowship at Tsinghua University. She joined Wiley as a scientific editor in 2022. 

     

    Nadav Ahituv, PhD is a Professor in the Department of Bioengineering and Therapeutic Sciences and the Director of the Institute for Human Genetics at the University of California, San Francisco. He received his PhD in human genetics from Tel-Aviv University working on hereditary hearing loss. He then did his postdoc, specializing in functional genomics, in the Lawrence Berkeley National Laboratory and the DOE Joint Genome Institute. His current work is focused on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes including morphological differences between species, drug response and human disease. His lab was one of the co-developers of massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements. In addition, he pioneered cis-regulation therapy (CRT), the use of gene regulatory elements as therapeutic targets for haploinsufficient disorders, and adipose modulation transplantation (AMT), a novel cancer cell therapy.

     

    Brandon Lê, PhD is a genetic epidemiologist deeply passionate about biomedical research and uncovering the genetic etiologies of rare human genetic disorders, as well as a science communicator experienced in translating findings from bench to bedside. He has worked in sickle cell disease (SCD), essential tremor (ET), epigenetic aging, glaucoma, and bipolar disorder (BPD), and his training is in genetic epidemiology, statistical genetics, and computational biology as applied to analyzing large biological datasets. He is currently a postdoctoral scholar at the Virginia Institute for Psychiatric and Behavioral Genetics (VIPBG) at Virginia Commonwealth University (VCU) in Richmond, VA investigating the genetic etiology of bipolar disorder. 

    Panel Discussion Topics

    The panelists introduce their backgrounds in plant molecular genetics, psychiatric genetics, functional genomics, gene therapy, and publishing.

    A presidential symposium on science communication prompts discussion about making genetics more accessible to people outside the field.

    The panel highlights the value of clear, audience-friendly language—for example, using “variant” rather than “mutation” when speaking to the public.

    Panelists reflect on communicating genetics across different levels of expertise, including for conference attendees outside a session’s specific subfield.

    A session on research beyond GWAS covers biobank studies, multi-omics and single-cell data calibration, false positives, machine-learning approaches to prioritizing genetic findings for drug discovery, and challenges in translating genetic discoveries into clinical trials.

    AI is improving predictions of regulatory elements and variant effects, particularly in the non-coding genome. The panel sees promise in AI-assisted variant prioritization while emphasizing the need for human oversight.

    Long-read sequencing and longer DNA synthesis may enable larger-scale genome engineering, high-throughput screening, and the study of combinatorial effects.

    Publishing advice: write early and alongside experiments. Doing so can reveal missing controls, incomplete notes, or gaps in the research while they’re still easy to address.

    Writing is a way of thinking, not just a way of documenting completed work.

    For computational research, documenting tools, parameters, and steps as you work can provide a strong foundation for the methods section.

    Sharing drafts with collaborators and readers from different backgrounds can improve clarity and help catch overlooked issues. Don’t wait for a perfect first draft before asking for feedback.

    Panelists discuss longer publication timelines and the strain they can place on trainees, as well as the challenge of finding enough qualified peer reviewers.

    Early-career researchers may be able to contribute to peer review, particularly with support from more experienced researchers.

    The publishing perspective shared in the discussion allows AI for language editing, but not for generating scientific insights; the panel also raises concerns about the quality of AI-heavy review papers.

    Authors can prepare for peer review by anticipating likely questions, addressing relevant alternative methods and analyses, and explaining limitations in the manuscript.

    Starting early, outlining the paper, and acknowledging potential reviewer concerns can help strengthen submissions and make revisions more efficient.

     

    ASHG 2026 Sessions & Events Mentioned

    Wiley's Advanced Portfolio × DNA Today Brunch Discussion — Thursday, October 22. Moderated by Kira Dineen, featuring Yuming Hu, Nadav Ahituv, and Brandon Le. The event explored emerging genetics research, translating discoveries into therapies, and scientific collaboration.

    Presidential Symposium: Communicating Science in an Uncertain World: Evidence, Storytelling, and Public Trust — Wednesday, October 21, 4:30–6:15 PM. Featuring Susan A. Slaugenhaupt, Alex Dainis, Natalie (Talia) Stroud, and Roxanne Khamsi.

    Nabsys CoLab: Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics — Thursday, October 22, 5:00–5:30 PM. Alka Chaubey, PhD, FACMG, Chief Medical and Genomics Office, Nabsys

    The Evolving Landscape of Genomic Newborn Screening with Global Experience and Emerging Challenges — Wednesday, October 21, 11:00 AM–12:00 PM.

    Genetic Counselor Shared Interest Group Meetup on Wednesday, October 21, from 9:45–10:45 AM

    Integrating AI and Knowledge Graphs for Human Genetics and Beyond: Innovations from the NIH Common Fund Data Ecosystem — Wednesday, October 21, 8:15–9:45 AM.

    Presentation of ASHG Artificial Intelligence Initiative Report — Thursday, October 22, 9:45–10:45 AM.

    Machine Learning-Driven Approaches to Variant Classification and Prioritization — Thursday, October 22, 8:15–9:45 AM.

    EHR-Based Computational and AI Approaches in Clinical Genetics — Thursday, October 22, 1:30–2:30 PM.

    Nabsys’ Resources 

    Nabsys to Showcase Electronic Genome Mapping for Hematologic Malignancies at ASHG 2026

    Nabsys Launches RepX™ for Repeat Expansion Analysis

    Nabsys’ Presence at ASHG 

    Electronic Genome Mapping Enables High-Resolution Cytogenomic Profiling of Hematologic Malignancies: A Proof-of-Principle Study

    Nabsys’ Posters at ASHG 

    Reviewers Choice Poster #5008F: CRISPR/Cas9 Optimization by Electronic Genome Mapping presented by John Thompson, PhD, Principal Scientist, Nabsys on Friday, October 23 from 2:30-4:30 PM EDT

    Poster #8146T: Genome-Scale Mapping of Human LINE-1 ORF2p Endonuclease Activity presented by Michael Gallagher, PhD, Software Applications Scientist, Nabsys on Thursday, October 22 from 4:15-6:15 PM EDT

    Poster #8132W: CRISPR/Cas9 Customization of Electronic Genome Mapping Repeat Expansion Assays presented by Kasra Tabatabaei, PhD, Application Scientist, Nabsys on Wednesday, October 21 from 2:30-4:30 PM EDT

    Poster #2031T: CRISPR-Assisted Electronic Genome Mapping for Robertsonian Translocations and FSHD presented by Erika Headrick, MS, Software Product Manager, Nabsys on Thursday, October 22 from 4:15-6:15 PM EDT

    Poster #2025F: Assessment of Structural and Copy Number Variants in Constitutional Samples Using Electronic Genome Mapping presented by Adam Smith, PhD, FCCMG, Clinical Laboratory Director, LabCorp on Friday, October 23 from 2:30-4:30 PM EDT

    Poster #8133F: Detection of Leukemia-Associated Structural Variants Using Electronic Genome Mapping Technology presented by Annarueber Lozar, M.S., Scientist, Nabsys on Friday, October 23 from 2:30-4:30 PM EDT

    Poster #2040F: Evaluation of the clinical utility of Electronic Genome Mapping Analysis in the detection of disease causing structural variants in rare genetic diseases presented by Dr. Kumiko Yanagi, National Center for Child Health and Development, Friday, October 23 from 2:30-4:30 PM EDT 

    Publishing Resources: 

    Wiley Advanced Portfolio 

    Wiley’s Journal Finder

    Genetics and Genomics: Advanced Science Collection 

    Precision medicine: From new tools to innovative applications: Advanced Portfolio Cross-journal Collections

    Wiley's AI guidelines for Authors

    What Makes a Successful Submission Wiley Blog Post

    Eligibility for access to Research4Life 

    Wiley Announce Team of Editors to Lead Advanced Portfolio Journals Expansion into Life Health Sciences

    Wiley Expands Advanced Journal Portfolio into Life and Health Sciences Deepens Physical Science Offering

     

    Relevant DNA Today Podcast Episodes:

    #392 Your DNA Is Not Static: Roxanne Khamsi on Mutation & Mosaicism

    #345 How To Talk About DNA Without Losing People: Strategies Part 1

    #350 How To Talk About DNA Without Losing People: Strategies Part 2

    #231 ChatGPT and AI In Genetics with Daniel Uribe

    #285 AI To Enhance Variant Curation with Daniel Uribe

    #337 How to Get Your Research Published: Insight from Wiley’s Advanced Portfolio Journal Editors

    #375 How Your Publication Can Fuel Genetic Innovation

    #363 ASHG 2025 Recap: AI Diagnostics, Genetics Publications & Losing NIH Funding

    #314 ASHG 2024 Recap

    #412 How Prenatal cfDNA Can Uncover Undiagnosed Maternal Cancer (AGBT-PH Coverage) 

    #416 How Baby KJ Became the First Patient Treated With Personalized CRISPR (AGBT-PH Coverage)

     

    Next Conference:
    Next stop on our conference road trip is Baltimore, MD for the National Society of Genetic Counselors (NSGC) annual conference. We can’t wait to see you there! If you see Kira, say hi and she will give you a DNA Today sticker! 

    Connect with DNA Today:
    You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.”

    Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios.

    Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network.

    DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. 

    Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. 

    Questions, partnership inquiries, and guest pitches can be sent to [email protected].
  • DNA Today: A Genetics Podcast

    #416 How Baby KJ Became the First Patient Treated With Personalized CRISPR

    2026-10-16 | 29 min.
    CRISPR has carried enormous promise since scientists first realized its potential to edit the human genome, but it has also raised some of the biggest ethical questions in modern genetics.

    In this episode, Kira Dineen sits down with Dr. Kiran Musunuru to trace the evolution of human gene editing, beginning with the controversial 2018 announcement that scientist He Jiankui had used CRISPR to edit human embryos in China, resulting in the birth of the world’s first gene-edited babies. The experiment, which targeted the CCR5 gene in an attempt to reduce susceptibility to HIV, sparked international condemnation and intensified debate over germline genome editing, where genetic changes could potentially be passed on to future generations.

    From there, the conversation shifts to a dramatically different application of CRISPR: treating serious genetic disease in an individual patient.

    Dr. Musunuru shares the remarkable story of Baby KJ, who was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency and became the first patient to receive a personalized CRISPR-based therapy designed specifically for his genetic variant. The team developed KJ’s customized base-editing treatment in approximately six months, moving from identification of his variant through preclinical testing, manufacturing, regulatory review, and ultimately treatment.

    Dr. Musunuru explains how KJ’s therapy works, what researchers have learned from his response so far, and whether his case could establish a new pathway for treating patients with ultra-rare genetic conditions who may never fit into a traditional drug-development model.

    This interview was recorded in person at AGBT Precision Health in Coronado, California, we caught up with Dr. Musunuru after a presentation. 

    Episode Discussion Topics:

    The 2018 announcement of the world’s first CRISPR-edited babies in China

    Why He Jiankui’s experiment targeting the CCR5 gene sparked global scientific and ethical backlash

    The difference between editing embryos and germline cells versus editing somatic cells in a patient

    What the CRISPR babies controversy taught the scientific community about oversight, regulation, and responsible use of gene-editing technology

    How the field of CRISPR medicine has evolved since 2018

    How naturally occurring PCSK9 variants helped reveal a powerful target for lowering LDL cholesterol and preventing cardiovascular disease

    Using CRISPR base editing to permanently turn down PCSK9 activity in the liver as a potential one-time treatment for high cholesterol

    The development of PCSK9 gene-editing therapies for patients with familial hypercholesterolemia and premature coronary artery disease

    The possibility of moving cardiovascular care from lifelong medications to durable, one-time genetic treatments

    How cardiovascular gene editing helped pave the way for applying similar base-editing technology to rare diseases like Baby KJ’s CPS1 deficiency

    What CPS1 deficiency is and why it can become life-threatening shortly after birth

    How Baby KJ’s diagnosis created an opportunity to pursue a personalized gene-editing treatment

    Why KJ’s specific genetic variant was a candidate for base editing

    How base editing differs from traditional CRISPR approaches that make double-stranded breaks in DNA

    Developing a gene-editing therapy specifically for a single patient

    Delivering the gene editor to liver cells using lipid nanoparticles

    Why the liver is an especially promising target for in vivo gene-editing therapies

    The collaboration between researchers, clinicians, biotechnology companies, regulators, and KJ’s family that made the treatment possible

    Navigating FDA review for a therapy that had never previously been given to a human

    Why KJ received multiple doses of the therapy

    Early signs that the treatment was having an effect, including increased dietary protein tolerance and reduced dependence on nitrogen-scavenging medication

    Why researchers are careful not to describe KJ’s treatment as a cure

    The importance of long-term monitoring for both effectiveness and potential safety concerns

    Evaluating off-target editing and other potential risks of personalized gene-editing therapies

    Whether creating an individual therapy for a single patient can realistically become scalable

    Moving from an “N-of-1” treatment toward gene-editing platforms that could be adapted for multiple patients with different variants

    How regulatory frameworks may need to evolve for personalized genetic medicines

    Which other rare genetic diseases could potentially benefit from this approach

    What Baby KJ’s story could mean for the future of precision medicine and gene editing

    About Dr. Kiran Musunuru
    Kiran Musunuru, MD, PhD, MPH, ML, MRA, is the Barry J. Gertz Professor for Translational Research at the Perelman School of Medicine at the University of Pennsylvania. He is Director of the Genetic and Epigenetic Origins of Disease Program within the Penn Cardiovascular Institute, Scientific Director of the Penn Center for Inherited Cardiovascular Disease, and Co-Director of the Penn Medicine/Children’s Hospital of Philadelphia Orphan Disease Center.

    Dr. Musunuru is a practicing cardiologist and physician-scientist whose research focuses on using genetics and gene-editing technologies to develop new treatments for cardiovascular, metabolic, and rare genetic diseases.

    He has also written extensively about the ethical and scientific implications of human genome editing, including the CRISPR babies controversy in his book The CRISPR Generation. 

    Along with Dr. Rebecca Ahrens-Nicklas and a large multidisciplinary team, Dr. Musunuru helped lead the development of the world’s first personalized CRISPR gene-editing therapy for Baby KJ. Their work was published in The New England Journal of Medicine in 2025.

    Baby KJ and Personalized Gene Editing
    KJ Muldoon was born with severe CPS1 deficiency, a rare urea cycle disorder caused by pathogenic variants in the CPS1 gene. Without adequate CPS1 enzyme activity, the body cannot efficiently process nitrogen generated from protein metabolism, which can lead to dangerously high ammonia levels.

    Researchers designed a customized CRISPR base-editing therapy targeting KJ’s specific disease-causing variant. The editor was delivered to the liver using lipid nanoparticles.

    KJ received multiple infusions of the personalized therapy. Researchers have reported that he has been able to consume more dietary protein, requires less nitrogen-scavenging medication, and has demonstrated improved metabolic stability. Researchers continue to monitor KJ closely to understand the therapy’s long-term safety, durability, and clinical benefit.

    Resources

    Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease

    Musunuru K, et al. New England Journal of Medicine. Published May 2025.

    The landmark publication describes the development and initial clinical results of KJ’s personalized base-editing therapy.

     The CRISPR Generation: The Story of the World’s First Gene-Edited Babies

    By Kiran Musunuru examines the science and ethical failures surrounding the creation of the first CRISPR-edited babies and what the case means for the future of human genome editing.

    “Chinese researcher claims first gene-edited babies” in the Associated Press

    The original article broke the news that the Chinese scientist He Jiankui had used CRISPR to edit human embryos, resulting in the birth of the world’s first gene-edited babies. 

    “In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia”

    Recent paper co-authored by Dr. Musunuru in The New England Journal of Medicine regarding people carrying loss-of-function variants of proprotein convertase subtilisin–kexin type 9 (PCSK9) have reduced levels of low-density lipoprotein (LDL) cholesterol and fewer atherosclerotic cardiovascular disease events than persons without such variants. VERVE-102 is an investigational base-editing therapy designed to durably inactivate PCSK9 in the liver.

    Children’s Hospital of Philadelphia: The Future of Personalized Medicine is Here: KJ’s Story
    Learn more about KJ, his family, and the multidisciplinary team that developed his personalized treatment.

    Penn Medicine: World’s First Patient Treated with Personalized CRISPR Gene Editing Therapy
    Overview of the science behind the treatment and the collaboration required to bring it into the clinic.

    Penn Medicine/CHOP Orphan Disease Center
    Dr. Musunuru serves as Co-Director of the center, which works to advance research and therapeutic development for rare diseases.

    AGBT Precision Health 
    We recorded this episode in person at AGBT Precision Health, which brings together leaders across genomics, precision medicine, research, and clinical care in an intimate setting that makes it easy to connect, learn, and have thoughtful conversations. 

    The conference is also hosted at a beautiful resort in the San Diego area, which makes the experience especially memorable. We highly recommend attending next year’s AGBT Precision Health meeting, taking place September 13–15, 2027, at the same gorgeous location. 

    Relevant DNA Today Episodes
    #288 CRISPR Cured Victoria Gray’s Sickle Cell: Part 1 & #289 Part 2

    Victoria Gray shares her experience living with sickle cell disease before becoming the first person treated with the CRISPR therapy that would later become Casgevy.

     

    #343 The First Child to Receive CRISPR for Duchenne? A Father’s Fight for a Cure

    Joe Jackson shares his family’s effort to develop a personalized CRISPR therapy for his son William, who has Duchenne muscular dystrophy.

     

    #198 CRISPR Ethics with Sam Sternberg

    Dr. Sam Sternberg explores the scientific, ethical, and regulatory questions surrounding CRISPR gene editing.

     

    #370 Genetics Wrapped: 2025 Top Advances in Genomic Medicine

    Drs. Eric Green and Sarah Tishkoff join our host Kira Dineen for our annual recap and reflection on the biggest genetics/genomics advancements this year! Kira’s top pick was this story of Baby KJ. 

     

    #399: PKU and the History of Newborn Screening

    In the first installment of our PKU series, we explore how the condition helped launch newborn screening and why early diagnosis can dramatically change a child’s future.

    #413 PKU Beyond the Diet: Food, Mental Health, and Daily Life

    In the second installment of our PKU series, Dr. Jennifer Brown and her daughter Lillian Isabella explore the realities of PKU, from food and family life to mental health and independence. 

    #412 How Prenatal cfDNA Can Uncover Undiagnosed Maternal Cancer

    Dr. Diana Bianchi discusses unexpected maternal findings from prenatal cell-free DNA screening. This was also recorded in-person at AGBT Precision Health 2026. 

    #141 Stan Crooke on Developing “n of 1” Treatments for Nano Rare Disease 

    Biotech titan Dr. Stan Crooke, who developed 20+ drugs, shares about his new n-Lorem Foundation, which develops ASO treatment for conditions affecting less than 30 people in the world. 

    #323 Supporting Ongoing Urea Cycle Disorder (UCD) Care

    Two UCD experts, Holly Bernal and Laurie Bernstein, share how clinicians can better engage patients in their own care to help them sustain their daily UCD management needs.

    Connect with DNA Today: 
    You never have to wait long for a new episode of DNA Today, we release episodes every Friday! In the meantime, explore our library of over 400 episodes on Apple Podcasts, Spotify, DNAToday.com, or wherever you listen to podcasts. Just search “DNA Today.”

    Prefer to watch? The video version of this episode is available on our YouTube channel and DNAToday.com. Select episodes are filmed in person, including some at the iconic NBCUniversal studios.

    Discover more podcasts exploring genetics, genomics, medicine, and science from our network, Gene Pool Media: The Science Podcast Network.

    DNA Today is hosted and executive produced by Kira Dineen, MS, LCGC, CG(ASCP)CM. Liv Davidson is our Social Media Lead and Eric Knaus is our Digital Marketing and Automation Lead. 

    Follow us at @DNATodayPodcast on all platforms including Instagram, X, BluSky, Threads, LinkedIn, Facebook, YouTube and our website, DNAToday.com. 

    Questions, partnership inquiries, and guest pitches can be sent to [email protected].
Fler podcasts i Life Science
Om DNA Today: A Genetics Podcast
Discover New Advances in the world of genetics, from technology like CRISPR to rare diseases to new research. For 14 years, multi-award winning podcast ”DNA Today” has brought you the voices of leaders in genetics. Host Kira Dineen brings her genetics expertise to interview geneticists, genetic counselors, patient advocates, biotech leaders, researchers, and more.***Best Science and Medicine Podcast Award Winner (2020, 2021 and 2022)***Learn more (and stream all 400+ episodes) at DNAtoday.com. You can contact the show at [email protected]. This show is part of "Gene Pool Media: The Science Podcast Network" head to GenePoolMedia.com to explore all our science themed shows. 
Podcast-webbplats

Lyssna på DNA Today: A Genetics Podcast, Robert och många andra poddar från världens alla hörn med radio.se-appen

Hämta den kostnadsfria radio.se-appen

  • Bokmärk stationer och podcasts
  • Strömma via Wi-Fi eller Bluetooth
  • Stödjer Carplay & Android Auto
  • Många andra appfunktioner
Sociala nätverk
v8.27.0 | © 2007-2026 radio.de GmbH
Built: 11/16/2026 - 1:18:40 PM